<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Most patients with <z:hpo ids='HP_0001946'>ketosis</z:hpo>-prone type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (KPD) discontinue insulin therapy and remain in near-normoglycemic remission </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to determine the effect of glucotoxicity on beta-cell function during remission in <z:mp ids='MP_0001261'>obese</z:mp> patients with KPD </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: Age- and BMI-matched <z:mp ids='MP_0001261'>obese</z:mp> African Americans with a history of KPD (n = 8), severe <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> but without <z:hpo ids='HP_0001946'>ketosis</z:hpo> (<z:hpo ids='HP_0001946'>ketosis</z:hpo>-resistant type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, n = 7), and <z:mp ids='MP_0001261'>obese</z:mp> control subjects (n = 13) underwent intravenous infusion of 10% <z:chebi fb="10" ids="4167">dextrose</z:chebi> at a rate of 200 mg per m(2)/min for 20 h </plain></SENT>
<SENT sid="3" pm="."><plain>beta-Cell function was assessed by changes in insulin and C-<z:chebi fb="7" ids="16670">peptide</z:chebi> concentrations during <z:chebi fb="10" ids="4167">dextrose</z:chebi> infusion and by changes in <z:hpo ids='HP_0011009'>acute</z:hpo> insulin response (AIR) and first-phase insulin release (FPIR) to arginine stimulation before and after <z:chebi fb="10" ids="4167">dextrose</z:chebi> infusion </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The mean +/- SD time to discontinue insulin therapy was 7.1 +/- 1.7 weeks in KPD and 9.6 +/- 2.3 weeks in <z:hpo ids='HP_0001946'>ketosis</z:hpo>-resistant type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (NS) </plain></SENT>
<SENT sid="5" pm="."><plain>During a 20-h <z:chebi fb="10" ids="4167">dextrose</z:chebi> infusion, changes in insulin, C-<z:chebi fb="7" ids="16670">peptide</z:chebi>, and the C-<z:chebi fb="7" ids="16670">peptide</z:chebi>-to-<z:chebi fb="105" ids="17234">glucose</z:chebi> ratio were similar among diabetic and control groups </plain></SENT>
<SENT sid="6" pm="."><plain>During <z:chebi fb="10" ids="4167">dextrose</z:chebi> infusion, subjects with <z:hpo ids='HP_0001946'>ketosis</z:hpo>-resistant type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> had greater areas under the curve for blood <z:chebi fb="105" ids="17234">glucose</z:chebi> than subjects with KPD and control subjects (P &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>The AIR and FPIR to arginine stimulation as well as <z:chebi fb="105" ids="17234">glucose</z:chebi> potentiation to arginine assessed before and after <z:chebi fb="10" ids="4167">dextrose</z:chebi> infusion were not different among the study groups </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Near-normoglycemia remission in <z:mp ids='MP_0001261'>obese</z:mp> African American patients with KPD and <z:hpo ids='HP_0001946'>ketosis</z:hpo>-resistant type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is associated with a remarkable recovery in basal and stimulated insulin secretion </plain></SENT>
<SENT sid="9" pm="."><plain>At near-normoglycemia remission, patients with KPD displayed a pattern of insulin secretion similar to that of patients with <z:hpo ids='HP_0001946'>ketosis</z:hpo>-resistant type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:mp ids='MP_0001261'>obese</z:mp> nondiabetic subjects </plain></SENT>
</text></document>